Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABLYF Ablynx	$50.63	$50.63	$12.50 ▼ $55.04	$3.81B	1.99	5,063 shs	N/A
ADPT Adaptive Biotechnologies	$11.98 +4.3%	$9.84	$3.33 ▼ $12.43	$1.79B	1.83	1.63 million shs	1.02 million shs
BOLD Boundless Bio	$1.06 -54.1%	$59.97	$1.00 ▼ $4.72	$23.95M	-1.34	100,927 shs	96,520 shs
IOVA Iovance Biotherapeutics	$1.75 +0.2%	$2.15	$1.64 ▼ $12.51	$584.39M	0.85	9.02 million shs	4.64 million shs
MNTA Momenta Pharmaceuticals	$52.48	$52.44	$12.21 ▼ $52.53	$6.25B	1.71	1.94 million shs	N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABLYF Ablynx	0.00%	0.00%	0.00%	0.00%	0.00%
ADPT Adaptive Biotechnologies	0.00%	+1.58%	+20.00%	+60.32%	+253.27%
BOLD Boundless Bio	0.00%	+1.44%	-12.45%	-19.16%	-75.12%
IOVA Iovance Biotherapeutics	0.00%	+3.79%	-4.15%	-41.53%	-76.27%
MNTA Momenta Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABLYF Ablynx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ADPT Adaptive Biotechnologies	3.346 of 5 stars	1.4	3.0	0.0	4.2	2.5	2.5	0.6
BOLD Boundless Bio	2.3635 of 5 stars	3.1	2.0	0.0	0.0	0.0	1.7	1.3
IOVA Iovance Biotherapeutics	4.709 of 5 stars	4.3	1.0	0.0	4.2	1.7	4.2	1.3
MNTA Momenta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABLYF Ablynx	0.00	N/A	N/A	N/A
ADPT Adaptive Biotechnologies	2.86	Moderate Buy	$10.57	-11.73% Downside
BOLD Boundless Bio	2.25	Hold	$4.00	279.15% Upside
IOVA Iovance Biotherapeutics	2.50	Moderate Buy	$12.22	596.82% Upside
MNTA Momenta Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MNTA, ADPT, ABLYF, IOVA, and BOLD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/2/2025	BOLD Boundless Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
5/28/2025	BOLD Boundless Bio	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$15.00 ➝ $3.00
5/27/2025	BOLD Boundless Bio	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$17.00 ➝ $2.00
5/12/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $8.00
5/12/2025	IOVA Iovance Biotherapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $10.00
5/12/2025	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/12/2025	IOVA Iovance Biotherapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABLYF Ablynx	$62.73M	60.74	N/A	N/A	$2.71 per share	18.68
ADPT Adaptive Biotechnologies	$178.96M	10.17	N/A	N/A	$1.37 per share	8.74
BOLD Boundless Bio	N/A	N/A	N/A	N/A	$6.76 per share	N/A
IOVA Iovance Biotherapeutics	$164.07M	3.57	N/A	N/A	$2.33 per share	0.75
MNTA Momenta Pharmaceuticals	$23.87M	261.69	N/A	N/A	$4.59 per share	11.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABLYF Ablynx	-$122.67M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	N/A	N/A	N/A	-74.84%	-62.79%	-24.55%	7/30/2025 (Estimated)
BOLD Boundless Bio	-$65.36M	N/A	N/A	N/A	N/A	N/A	-41.60%	-34.53%	N/A
IOVA Iovance Biotherapeutics	-$372.18M	-$1.24	N/A	N/A	N/A	-176.49%	-49.71%	-39.18%	8/6/2025 (Estimated)
MNTA Momenta Pharmaceuticals	-$290.05M	-$3.03	N/A	N/A	N/A	-757.61%	-61.44%	-45.28%	N/A

Latest MNTA, ADPT, ABLYF, IOVA, and BOLD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q1 2025	BOLD Boundless Bio	-$0.68	-$0.71	-$0.03	-$0.71	N/A	N/A
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	$52.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABLYF Ablynx	N/A	N/A	N/A	N/A	N/A
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
BOLD Boundless Bio	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
MNTA Momenta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABLYF Ablynx	N/A	N/A	N/A
ADPT Adaptive Biotechnologies	N/A	2.92	2.82
BOLD Boundless Bio	0.35	22.15	22.15
IOVA Iovance Biotherapeutics	N/A	4.18	3.64
MNTA Momenta Pharmaceuticals	N/A	6.38	6.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABLYF Ablynx	N/A
ADPT Adaptive Biotechnologies	99.17%
BOLD Boundless Bio	N/A
IOVA Iovance Biotherapeutics	77.03%
MNTA Momenta Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ABLYF Ablynx	N/A
ADPT Adaptive Biotechnologies	6.40%
BOLD Boundless Bio	21.10%
IOVA Iovance Biotherapeutics	10.30%
MNTA Momenta Pharmaceuticals	3.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABLYF Ablynx	N/A	75.25 million	N/A	Not Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	142.19 million	Optionable
BOLD Boundless Bio	207	22.39 million	17.66 million	No Data
IOVA Iovance Biotherapeutics	500	333.93 million	299.54 million	Optionable
MNTA Momenta Pharmaceuticals	131	119.03 million	N/A	Optionable

MNTA, ADPT, ABLYF, IOVA, and BOLD Headlines

Recent News About These Companies

Stephanie Schonewald

October 31, 2024 | ipwatchdog.comI

J&J, with adult approval in sight, posts adolescent myasthenia gravis data on $6.5B FcRn blocker

October 17, 2024 | fiercebiotech.comF

J&J launches gMG market bid with nipocalimab filing

September 2, 2024 | pharmaphorum.comP

Johnson & Johnson Files for First FDA OK of Nipocalimab

August 31, 2024 | marketwatch.com

Impact of Bleeding Complications on Outcomes After Percutaneous Coronary Interventions

April 12, 2024 | medscape.comM

Acquired patents aid J&J defense of top-selling drug from biosimilar challenge

March 30, 2023 | biopharmadive.comB

Genoptix, Momenta Shares Headed for Gains

February 28, 2023 | thestreet.com

Momenta Pharma Competitor Lodges Ethics Complaint Against FDA Boss, WSJ Reports

August 13, 2022 | xconomy.comX

Patent infringement cases move to the fast lane in India

June 13, 2022 | thepharmaletter.comT

Johnson & Johnson, Momenta Pharma file lawsuit against Natco, Mylan in US

May 25, 2022 | msn.com

Eastman Kodak, Rambus: After-Hours Trading

April 30, 2022 | thestreet.com

Innovation leader

April 8, 2022 | udel.eduU

Momenta Pharmaceuticals, Inc. Common Stock (MNTA)

August 3, 2021 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
By Chris Markoch | June 29, 2025
View 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

MNTA, ADPT, ABLYF, IOVA, and BOLD Company Descriptions

Ablynx OTCMKTS:ABLYF

$50.63 0.00 (0.00%)

As of 04/30/2019

Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

Adaptive Biotechnologies NASDAQ:ADPT

$11.98 +0.50 (+4.32%)

Closing price 07/3/2025 03:56 PM Eastern

Extended Trading

$12.03 +0.05 (+0.45%)

As of 07/3/2025 04:47 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Boundless Bio NASDAQ:BOLD

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.

Iovance Biotherapeutics NASDAQ:IOVA

$1.75 +0.00 (+0.23%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$1.76 +0.00 (+0.11%)

As of 07/3/2025 04:58 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Momenta Pharmaceuticals NASDAQ:MNTA

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time